Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze
Executive Summary
With Haegarda holding a convenience edge over Cinryze for HAE prophylaxis, Shire now has data showing that SHP616 also offers significant prevention of HAE attacks. How ‘616 fits into Shire’s overall HAE strategy is unclear.
You may also be interested in...
With Takhzyro Approval, Shire Could Reclaim HAE Prophylaxis Market From CSL Behring
Offering better efficacy than Shire’s existing HAE therapies and dosing convenience compared to CSL Behring’s prophylactic Haegarda, the specialty pharma may take back market share lost to its competitor and consolidate its leadership in the space.
Mum On Takeda, Shire Outlines Two-Division Performance
Before the March 28 announcement of Takeda’s interest in buying Shire, the focus of Shire’s first quarter earnings call was expected to be the initial reporting of financial results for rare disease and neuroscience as separate units. Sales for the former grew, but declined for the latter.
Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio
Immunology portfolio yielded 14% sales growth in 2017, led by growing subcutaneous immunoglobulins and a still-rising HAE franchise. Dry eye drug Xiidra was another 2017 growth catalyst.